Table 2.

Association of Tregs and MDSCs and other cancers except for HCC.

Cancer	Immune Suppressive Cells		Treatments, Future Treatments or Other Uses	References
	Tregs	MDSCs
Large B cell lymphoma	○		prognostic biomarker	Ahearne et al. [44]
Non-Hodgkin Lymphoma	○		prognostic biomarker	Pinheiro et al. [45]
Myeloma	○		CTLA-4 antibody	Braga et al. [46]
	○	○	High-dose IL2 followed by Sorafenib	Monk et al. [47]
		○	Adjuvant GM-CSF	Daud et al. [48]
	○	○	prognostic marker	Brimnes et al. [49]
Ovarian Cancer	○		prognostic biomarker	Brtnicky et al. [50]
Mouse model (liver metastasis model)		○	Anti-PD-L1 antibody	Ilkovitch et al. [51]
Esophageal Cancer	○		Down-regulation of B7-H1 expression	Chen et al. [52]
non-small-cell lung cancer	○		prognostic biomarker	Hasegawa et al. [53]
				Yukawa et al. [54]
		○	prognostic biomarker	Liu et al. [43]
Lewis lung carcinoma (mouse model)	○		anti-miR214	Yin et al. [55]
Pancreatic ductal adenocarcinoma	○		prognostic biomarker	Luardi et al. [57]
Renal Cell Carcionam	○	○	High-dose IL2 followed by Sorafenib	Monk et al. [47]
		○	prognostic biomarker	Mirza et al. [58]
		○	prognostic biomarker	Kusmartsev et al. [59]
Solitary Fibrous Tumor		○	Sunitinib malate	Tazzari et al. [60]
Thyroid cancer	○		Inhibition of FOXP3	Chu et al. [61]
Glioblastoma	○		prognostic marker	Soyour E et al. [62]
Colon carcinoma (mouse model)	○	○	c-kit antibody	Pan et al. [63]